Healthcare Industry News: alpha-1
News Release - December 1, 2006
Talecris Continues Global Expansion into Europe
Talecris Biotherapeutics GmbH established as a wholly-owned sales and service organization to serve more than 15 European countries; represents second expansion in past nine monthsRESEARCH TRIANGLE PARK, N.C. & FRANKFURT, GERMANY, December 1 (Healthcare Sales & Marketing Network) - Talecris Biotherapeutics Inc. today announced the establishment of Talecris Biotherapeutics GmbH, its European headquarters in Frankfurt, Germany. Europe represents the second expansion in 2006 for the North Carolina-based biotherapeutics manufacturer, completing the next regional phase in the company's ongoing global expansion plan.
Building on significant success and milestones achieved since its launch, Talecris has grown rapidly over the last 20 months and is well-positioned for continued success and growth, while remaining committed to its patients, employees, customers, and continuing product pipeline innovations.
Commenting on Talecris' establishment of a European presence, Professor Claus Vogelmeier, M.D., Division of Pulmonary Diseases, University Hospital Marburg, Germany, said "We are pleased to continue working with Talecris, now in Europe, to help physicians identify and treat patients with alpha-1 antitrypsin deficiency, also known as genetic emphysema. Their commitment to invest in research projects and patient and professional support programs will continue to strengthen our ability to improve patient outcomes."
With the expansion to Europe, Talecris also is now positioned to work closely with physicians and their patients to improve clinical care of primary immune deficiency patients. According to Volker Wahn, M.D., of the Immunodeficiency Center of the Charite (IDCC), Berlin, Germany, "Talecris has been a valuable industry partner in efforts to educate and inform physicians about PID. Now patients in Europe may benefit from a stronger Talecris presence."
Talecris has experienced tremendous success in its first 20 months of business. By the end of June 2006, as one of the leading biological products manufacturers, Talecris achieved sales of more than $1 billion, and has grown to employ more than 3,000 talented employees. The company supplemented its business with the acquisitions of Precision Pharma Services, which provides additional fractionation capacity, and again in 2006 by acquiring 58 plasma collection centers from International BioResources to complete the vertical integration of the business.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, which earned revenues exceeding $1 billion through the year ending June 30, 2006, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 3,000 talented people worldwide. To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com or www.talecris.de.
Source: Talecris Biotherapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
